Yeah, was going to post similar, have over 800 patients in an area high in NASH, should help with the data, which the data they already have is encouraging. This was the downfall of other ccr5 drugs, leronlimab seems to excel with different way of inhibiting than those.

“It is important to note that in people living with HIV, the occurrence of NAFLD is higher than in the general population, affecting 30 to 65 percent of the HIV population1. Medications that HIV patients take as part of their regimen may cause fatty liver development and have other hepatoxic effects. As we approach 1,000 patients involved in our HIV trials, we have not observed the hepatoxicity that has been evident in other CCR5 antagonists and HIV medications.”